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Background: Prescription drug sales may vary considerably across regions and over time. This study aimed to
assess whether there is an association between mean drug sales and prevalence of excessive use in a range of
psychotropic prescription drugs with an abuse potential, and if so, whether the variation in mean drug sales mostly
reflects variation in the prevalence of excessive use or mostly reflects variation in non-excessive use.
Methods: Data on all filled prescriptions taken from the Norwegian prescription database for 10 drugs with an
abuse potential (pain relievers, anxiolytics, and hypnotics) during one calendar year (2005) in Norway (n = 4 053
624) included number of defined daily doses (DDD). These were aggregated to individual level (n = 815 836) and
county level (n = 19).
Results: Analyses of individual level data showed that the distribution of drug use was skewed; those who used
more than 365 DDD per year accounted for almost half of the sales of both anxiolytics and hypnotics. At the
county level, the mean sales per inhabitant and the prevalence of excessive users were closely correlated, but
both prevalence of non-excessive use and prevalence of excessive drug use were associated with the county-wise
variation in mean drug sales.
Conclusion: Despite a strong individual control of access to psychotropic drugs through health personnel’
prescribing, a small proportion of users account for a large fraction of the sales of these drugs. The sales vary
significantly between regions and this variation is closely associated with the prevalence of excessive users. This
suggests that sales figures as such may be used as an indicator to monitor variations in excessive use between
regions and over time, and to evaluate interventions targeting over-prescription and excessive use.
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Drug salesBackground
Opioids, hypnotics, and anxiolytics are drugs mainly pre-
scribed for the treatment of pain, insomnia or anxiety.
In high income countries these drugs are widely used,
however, they have a potential for abuse and are also
used in excessive and non-therapeutic amounts by some
patients [1-3]. Such excessive long-term use carries an
elevated risk of many and diverse negative consequences.
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article, unless otherwise stated.that apply to all these drugs [4-6], the risks of long-term
use of hypnotics and anxiolytics include also impaired cog-
nitive functions and memory loss, impaired motor function
and risk of falls and injuries, paradoxical effects such as
anxiety, restlessness and insomnia, and aggravated demen-
tia [7]. In most countries such drugs are therefore subject
to formal control, most often in terms of a prescription sys-
tem [8], a system of scheduling, and guidelines advocating
restricted use of these drugs. Nevertheless, excessive use or
abuse of pharmaceutical drugs also occurs under such re-
gimes [9]. To some extent this can be attributed to diverted
drugs and access from illegal markets [10], but some pa-
tients are also prescribed excessive amounts of these drugsd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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addressed here.
The prescribing of opioids, hypnotics and anxiolytics
varies enormously between countries, but a significant
variation within countries is also observed, both between
regions and over time [12]. For instance, prescriptions of
benzodiazepines in Spain and the USA were four to five
times higher than that in Germany [13] and in the USA,
prescriptions of opioid analgesics varied by a factor of 12
between states [14]. Most often a prescription system
will allow for generating wholesale statistics of drug sales
at the aggregate level, but it would be important to know
whether – or to what extent – the aggregate variation in
these sales is indicative of variation in the prevalence of
excessive use and abuse of these drugs.
As the prescription system is meant to prevent exces-
sive use and thereby interfere with a ‘natural’ distribu-
tion of drug use, we may assume that the prescription
system’s – and mainly the prescribers’ – ability to obtain
this goal, will affect the distribution of drug use. Veryb
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Figure 1 Hypothetical distributions of drug use. The area under the dis
and c than a. The filled area in the right tail of the distribution is the excesdifferent distribution patterns of use could therefore –
in principle - underlie an overall variation in total sales.
The overall variation could e.g. be due to variation in
the number of users and the amount of use among non-
excessive users with little or no variation in the preva-
lence of excessive use. Or vice versa; the overall variation
in sales could be due to variation in the number of ex-
cessive users and their consumption. Or the variation in
sales could be due to some combination of the two.
Obviously, the nature of this underlying distribution is
not only of theoretical relevance, but also important
from a public health perspective. Thus, if the variation
could be ascribed mainly to the number of users, but
not excessive use, high sales figures could suggest a
higher morbidity rate in the studied population or a
higher coverage of the target population. This is illus-
trated with the hypothetical drug use distributions in
Figures 1a and b; the higher total drug use in 1b com-
pared to 1a solely reflects an increase in number of non-
excessive users, whereas the number of excessive userstribution curve is the total amount of drug use, which is larger in b
sive drug use, which is the same in a and b and larger in c.
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mainly reflected variation in excessive use, an increase in
total drug use would reflect a more right-skewed dis-
tribution, as illustrated when comparing Figures 1a to
c. In the latter scenario, this would mean that sales
figures as such could be used to monitor variations in
excessive use. If this were true, wholesale figures,
more readily available, could be used to monitor dif-
ferences in excessive use between regions and over
time, and to evaluate interventions targeting over-
prescription and excessive use.
So far, the distribution pattern of the consumption of
prescription drugs with an abuse potential has scarcely
been addressed in empirical studies. Indeed, surveys in
general population samples and in institutionalized and
other patient samples have demonstrated some aspects
of the distribution of consumption, such as differences
in prevalence of use and excessive use with respect to
gender and age [15,16]. However, few studies have ad-
dressed a possible association between total sales of psy-
choactive drugs and prevalence of excessive use of these
drugs, yet there is some indirect evidence suggesting this
type of association. In the USA, both sales of opioids
and treatment admissions for opioid abuse have in-
creased significantly and in a parallel manner from 1999
to 2009 [17]. In a previous study [18], we examined the
distribution pattern of one prescription drug with abuse
potential (carisoprodol) and found that there was a
strong and positive association between sales of cariso-
prodol and prevalence of excessive use. In other words,
high total sales of this drug were indicative of high
prevalence of excessive drug use, and vice versa. The
aim of the present study was to pursue this finding and,
by looking at the 10 most accessible prescription drugs
with an abuse potential, to assess whether a close associ-
ation between total drug sales and prevalence of exces-
sive use could be found for a wider range of prescription
drugs with an abuse potential, and if so, whether the
variation in total drug sales mostly reflects variation in
prevalence of excessive use or also reflects variation in
non-excessive use.
Methods
Data source
Drug use data were retrieved from the Norwegian
Prescription Database (NorPD). Access to the data was
applied for and granted by the Norwegian Public Health
Institute. The NorPD covers the entire Norwegian popu-
lation (5.0 million inhabitants). From 1 January 2004, all
pharmacies in Norway were obliged by law to submit
electronic data every month on all prescriptions to the
Norwegian Institute of Public Health. The NorPD con-
tains information on all prescription drugs, reimbursed
or not, dispensed at Norwegian pharmacies to individualpatients who live outside institutions [19,20]. Over-the-
counter drugs not requiring prescriptions are not regis-
tered. For each prescription the following data were
collected and used in the present analyses: patients’
unique identifiers (encrypted), county of residence, and
drug information; i.e. which drug based on the anatom-
ical–therapeutic–chemical code (ATC-code) and the
amount of the drug prescribed converted into number
of defined daily doses (DDD). The DDD is the assumed
average maintenance dose per day for the drug’s main
indication in adults, it is assigned by the WHO collabor-
ating centre and has been used in similar types of studies
previously [21]. The data collected for the present study
comprised 10 of the most widely used prescription drugs
with an abuse potential in Norway [22], but not drugs
on the narcotics list, like morphine and other opioids
which are heavily restricted. The drugs were as follows
(ACT-code, DDD and main use in parentheses): cari-
soprodol (M03BA02, 1400 mg, centrally acting muscle
relaxant), codeine (N02AA59, 150 mg, opioid pain
reliever), diazepam (N05BA01, 10 mg, anxiolytic), oxaze-
pam (N05BA04, 50 mg, anxiolytic), nitrazepam (N05CD02,
5 mg, hypnotic), flunitrazepam (N05CD03, 1 mg, hypnotic),
zopiclone (N05CF01, 7,5 mg, hypnotic), and zolpidem
(N05CF02, 10 mg, hypnotic), that were filled in Norwegian
pharmacies during the calendar year 2005. The year 2005
was chosen as this was the last year before carisoprodol
came under scrutiny in the Norwegian market. The num-
ber of prescriptions for alprazolam (N05BA12, anxiolytic)
and clomethiazole (N05CM02, hypnotic) were too few to
analyse separately, but data on prescriptions for these drugs
were included in summary measures of anxiolytic drugs
and hypnotic drugs, respectively. The data set comprised a
total of 4,053,624 prescriptions. Data on population figures
were obtained from Statistics Norway.
Excessive use of addictive drugs
Different definitions of excessive use of prescription
drugs in general have been applied previously; for in-
stance: a set amount of prescribed drug within a certain
time period (e.g. more than 2 DDDs/day over a 30-day
period) [23]; large prescriptions (e.g. more than twice
the recommended amount in any prescription) [24]; and
frequent prescribing (e.g. only a few days between pre-
scriptions) [25]. In Norway, the guidelines for prescrib-
ing hypnotics and sedatives are that these drugs should
be used only temporarily; daily use should be limited to
the shortest possible time and no more than two to four
weeks. Intermittent treatment is recommended for pa-
tients with chronic insomnia [26]. Carisoprodol was not
to be used for more than 5–10 days. The use of opioids,
including codeine use should be restricted to a mini-
mum, but no strict time is indicated. Thus, we consid-
ered drug consumption exceeding daily use of a defined
Rossow and Bramness BMC Public Health  (2015) 15:288 Page 4 of 9dose for a day (DDD) over an entire year as excessive
use and we applied three indicators of excessive drug
use for each drug; those who filled prescriptions during
a year which amounted to: a) more than 365 DDDs, b)
more than 730 DDDs and c) more than 1095 DDDs.
Strategy of analyses
First, all prescriptions were aggregated to the individual
level (n = 815 836), summarizing the amount of pre-
scribed drugs in DDDs during the calendar year for each
drug and drug group (Figure 2). By applying individual
level data for the country as a whole, we described for
each drug first the prevalence of past year users, the
mean amount of drug use per inhabitant and year in the
overall population and the mean and median amount
per year among the users. Then, for each drug we de-
scribed the prevalence of excessive users (applying vari-
ous thresholds for excessive use) and the fraction of
drug sales that these users accounted for.Aggregation key = 
unique patient ID numbe
Aggregation key = 
patient county of res
Figure 2 Illustration of aggregation of filled prescriptions. Each eleme
numbers are aggregated from prescriptions to patients and from patients tNext, the individual level data were aggregated to the
county level (n = 19) (Figure 2). We assessed whether
there was any significant variation in mean drug sales
and prevalence of excessive users between counties,
applying maximum-minimum value ratios. We then
assessed whether drug sales and prevalence of excessive
users correlated, applying Spearman’s rank correlation
coefficient. Due to low numbers, the third indicator of
excessive drug use (>1095 DDDs/year) could not be in-
cluded in the analyses at the county level.
Finally, we assessed to what extent the variation in
drug sales between counties could be attributed to the
prevalence of excessive users and the prevalence of
non-excessive users. Linear ordinary least square (OLS)
regression models were estimated, and input variables
included by model fit criteria. In these analyses input
variables comprised prevalence figures for three mutu-
ally exclusive categories of drug users; non-excessive
users (<365 DDDs/year), moderately excessive usersPrescriptions 
n=4053624 
Patients
n=815 836
Counties
n=19
r
idence
nt illustrates the amount of a specific drug (in number of DDDs). The
o counties.
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DDDs/year). Beta coefficients were obtained to assess
the relative importance of the input variables to predict
variation in drug sales and model R square was obtained
to assess the overall predictive value of the input vari-
ables included in each model.
All analyses were first carried out for each drug. Then all
analyses were carried out for two main groups of drugs; all
anxiolytic drugs (diazepam, oxazepam, and alprazolam) and
all hypnotic drugs (nitrazepam, flunitrazepam, zopiclone,
zolpidem, and clomethiazole), and finally all analyses were
carried out for all 10 drugs together (carisoprodol, codeine,
diazepam, oxazepam, alprazolam, nitrazepam, flunitraze-
pam, zopiclone, zolpidem, and clomethiazole).
Results
Distributions at the individual level
The prevalence of users and the mean sales per inhabit-
ant varied significantly between the eight drugs; the
highest prevalence of users was found for codeine (8.8%
of the population) and zopiclone (6.3%) and the lowest
for flunitrazepam (0.3%). Within one year, altogether
17.7% of the Norwegian population had filled one or
several prescriptions for one or several drugs with an
abuse potential. Mean sales per inhabitant per year
were highest for zopiclone (10 DDD/inhabitant/year)
and about equally low for carisoprodol, flunitrazepam
and zolpidem (about 1 DDD/inhabitant/year) (Table 1).
Mean consumption per user and year was particularly
high for flunitrazepam and nitrazepam. For all drugs
the mean consumption among the users exceeded the
median considerably, implying a distribution heavily
skewed to the right (Table 1).
In line with the skew distributions we observed that
a substantial proportion of users filled prescriptionsTable 1 Number of users (in 1000), prevalence of users per 10
year in DDD, and mean and median consumption per user pe
In total population
Number of
users in 1000
Prevalence of users
per 1000 populatio
Carisoprodol 84 18.2
Codeine 406 88.2
Diazepam 153 33.2
Oxazepam 125 27.1
Nitrazepam 44 9.6
Flunitrazepam 14 3.0
Zopiclone 288 62.5
Zolpidem 42 9.1
Anxiolytics (including alprazolam) 266 57.8
Hypnotics (including clomethiazole) 361 78.4
All studied drugs 816 177.2exceeding 365 DDD per year, this proportion was par-
ticularly high for hypnotics (Table 2). The proportion of
users filling prescriptions exceeding 730 DDD per year
was not very high, but far from negligible, i.e. it was
mostly around 1%, yet among flunitrazepam users, 6%
filled prescriptions exceeding 730 DDD per year
(Table 2). These excessive users accounted for a dispro-
portionately high fraction of the total drug sales. Those
who filled prescriptions exceeding 365 DDDs accounted
for almost half of the total sales of anxiolytics and hyp-
notics, and those who filled prescriptions exceeding 730
DDDs accounted for almost one fourth of all sales of an-
xiolytics and for 13% of the total sales of hypnotics
(Table 2). Even the very few who filled prescriptions ex-
ceeding 1095 DDDs accounted for a non-negligible frac-
tion of the total drug sales; more specifically, they
accounted for 15.8% of all anxiolytics sales and 6.4% of
all hypnotics sales (Table 2).Distributions and associations at the county level
The mean sales – and assumingly consumption – per in-
habitant varied considerably across counties; the
maximum-minimum ratio was of the magnitude of 2 to
3 for the various drug categories, and the variation in
the prevalence of excessive users tended to be higher
(Table 3). For all drug categories the mean sales per in-
habitant was closely associated with the prevalence of
users receiving more than 365 DDDs/year (Spearman’s
rank correlation coefficients ranging between 0.87 and
0.99) (Table 3). There was also a positive and statistically
significant correlation between mean sales and preva-
lence of users receiving more than 730 DDDs/year, yet
of a somewhat more moderate magnitude (ranging be-
tween 0.52 and 0.89) (Table 3).00 population, mean consumption per inhabitant and
r year in DDD, by psychoactive drug category
Among users
n
Mean DDD per inhabitant
per year
Mean DDD per
year and user
Median DDD per
year and user
0.82 44.9 7.5
4.35 49.3 12.5
3.74 112.9 45.0
2.23 82.1 29.4
2.06 213.6 120.0
0.80 263.9 180.0
9.98 159.5 90.0
1.11 120.8 45.0
6.8 118.4 37.5
14.0 177.8 100.0
26.0 146.5 33.3
Table 2 Proportion of users with excessive use and the fraction of total consumption accounted for by excessive users
by category of excessive use; > 365 DDD/year, > 730 DDD/year, > 1095 DDD/year, and by psychoactive drug category
> 365 DDD > 730 DDD > 1095 DDD
Proportion
of users (%)
Proportion of
consumption (%)
Proportion of
users (%)
Proportion of
consumption (%)
Proportion of
users (%)
Proportion of
consumption (%)
Carisoprodol 1.9 26.4 0.4 9.8 0.1 5.4
Codeine 2.5 29.9 0.5 10.2 0.1 4.5
Diazepam 7.6 43.3 1.6 15.4 0.5 7.2
Oxazepam 4.2 31.3 0.8 10.6 0.2 4.5
Nitrazepam 19.9 53.9 3.3 16.7 1.1 8.1
Flunitrazepam 24.9 62.0 6.1 27.9 2.2 14.9
Zopiclone 12.6 42.0 1.4 9.7 0.4 4.3
Zolpidem 8.5 41.3 1.3 12.6 0.4 6.5
Anxiolytics (including alprazolam) 7.4 47.4 2.1 23.9 0.9 15.8
Hypnotics (including clomethiazole) 15.1 47.6 2.1 13.2 0.7 6.5
All studied drugs 11.6 58.7 3.4 30.8 1.6 19.6
Table 3 Variation in mean consumption and prevalence of excessive users (range and max-min ratio) between
counties and correlations between mean consumption and prevalence of excessive users (>365 DDD/year; > 730
DDD/year) at county level
Mean consumption
per inhabitant
Prevalence w/ >365 DDD
per 1000 population
Prevalence w/ >730 DDD
per 1000 population
Correlations with mean
consumption
range and
max-min ratio
range and max-min ratio range and max-min ratio > 365 DDD Per
1000 inhabitants
> 730 DDD Per
1000 inhabitants
Carisoprodol 0.40 - 1.09 0.14-0.48 0.02-0.15 0.87** 0.52*
2.7 3.4 7.5
Codeine 2.92 - 6.76 1.26-3.56 0.25-0.60 0.97** 0.72**
2.3 2.8 2.4
Diazepam 2.05-5.99 1.20-3.91 0.20-0.81 0.95** 0.82**
2.9 3.3 4.0
Oxazepam 1.11-3.83 0.45-2.04 0.10-0.38 0.96** 0.85**
3.5 4.5 3.8
Nitrazepam 1.11-3.49 1.00-3.30 0.11-0.48 0.99** 0.85**
3.1 3.3 4.4
Flunitrazepam 0.43-1.41 0.36-1.29 0.05-0.37 0.97** 0.85**
3.3 3.6 7.4
Zopiclone 6.07-13.17 3.70-11.11 0.37-1.42 0.99** 0.87**
2.2 3.0 3.0
Zolpidem 0.65-1.62 0.44-1.23 0.03-0.22 0.95** 0.88**
2.5 2.8 7.3
Anxiolytics (including
alprazolam)
3.87-10.84 2.12-7.10 0.60-2.17 0.98** 0.89**
2.8 3.3 3.6
Hypnotics (including
clomethiazole)
8.32-18.23 5.86-16.61 0.66-2.50 0.99** 0.86**
2.2 2.8 3.8
All studied drugs 16.25-33.86 13.28-29.04 2.98-9.65 0.99** 0.95**
2.1 2.2 3.2
Levels of statistical significance: *p < 0.05, **p < .01.
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sales across counties was merely reflecting variation in
excessive use or whether it also reflected the prevalence
of users. For all drugs the prevalence of non-excessive
users (<365 DDDs/year) and the prevalence of excessive
users both contributed significantly to explain the vari-
ation between counties in drug sales per inhabitant. The
beta coefficients – and thus the relative importance – of
prevalence of moderately excessive users (365–730
DDDs/year) varied somewhat across drug categories and
were higher than that for non-excessive users and highly
excessive users (>730 DDDs/year) with respect to co-
deine, anxiolytics and hypnotics (Table 4). For five of the
eight drugs (diazepam, nitrazepam, flunitrazepam, zopi-
clone and zolpidem) and for both drug groups (anxio-
lytics and hypnotics), even the prevalence of highly
excessive users contributed significantly to the variation
in drug sales between counties (Table 4).Discussion
This study has demonstrated that across a wide a range
of prescription drugs with an abuse potential the distri-
bution of consumption as measured by filled prescrip-
tions was heavily skewed, and that the relatively few
excessive users accounted for a disproportionately high
fraction of the drug sales. This was true for drugs like
benzodiazepine anxiolytics and hypnotics, z-hypnotics
and weak opioid analgesics. Moreover, the sales and
prevalence of excessive users varied significantly between
counties and there was a strong positive correlation be-
tween the two. Thus, the prevalence of excessive users
accounted for much of the variation in drug sales, yetTable 4 Associations between mean sales of psychoactive dru
excessive users by type of psychoactive drug
Prevalence of non-
excessive users
Pr
us
Regr
coeff
SE p-value Beta Re
co
Carisoprodol 0.026 0.007 .002 .543 1.2
Codeine - - - 1.7
Diazepam 0.066 0.006 <.001 .403 0.7
Oxazepam 0.052 0.004 <.001 .536 1.0
Nitrazepam 0.105 0.010 <.001 .353 0.5
Flunitrazepam 0.142 0.013 <.001 .351 0.4
Zopiclone 0.070 0.015 <.001 .192 0.8
Zolpidem 0.069 0.007 <.001 .409 0.6
Anxiolytics (also including alprazolam) 0.024 0.006 .002 .200 1.0
Hypnotics (also including clomethiazole) 0.072 0.019 .002 .182 0.7
All studied drugs 0.051 0.018 .012 .118 0.7
Unstandardized regression coefficients, standard errors of estimates, standardized regress
Only statistically significant associations are presented.the prevalence on non-excessive users also contributed
to the variation in drug sales between counties.
Our observations of a very skewed distribution of use
of prescription drugs with an abuse potential resemble
those from some previous studies of such drugs [27].
Moreover, these findings add to a meagre literature on
the distribution of prescription drug use and the associ-
ation between drug sales on the one hand and indicators
of excessive use on the other. It demonstrates that what
we found earlier for carisoprodol alone [18] is applicable
to a series of drugs with abuse potential, indicating that
whole sales of various drugs with an abuse potential is
closely related to excessive use. This is in line with previ-
ous observations of a correlation between wholesale of
prescription opioids and treatment admissions [17], and
relevant to the observed correlations between wholesale
and overdoses of opioid pain relievers [17,28] and of car-
isoprodol [29,30].
Study strengths and limitations
The major strength of this study is that we have a
complete prescription register providing data on all psy-
chotropic drug sales in the non-institutionalized popula-
tion. The data are not subject to attrition bias and
reporting bias as in population surveys. The data are ac-
curate with respect to drug, drug category and dispensed
amounts as opposed to self-reported data. In this study
we have large numbers of patients who have filled pre-
scriptions, which allows for comparisons of distribution
measures across geographical units, i.e. counties.
The study limitations include not having a clinical
diagnosis of drug abuse, but having to rely on figures of
filled prescriptions. We have attempted to compensategs (in DDD/1000 inh/year) and prevalence of users and of
evalence of excessive
ers > 365 DDD, < 730 DDD
Prevalence of excessive
users > 730 DDD
Model R2
gr
eff
SE p-value Beta Regr
coeff
SE p-value Beta
43 0.412 .008 .439 - - - 0.864
61 0.120 <.001 .961 - - - 0.923
71 0.057 <.001 .483 1.176 0.172 <.001 .231 0.989
58 0.078 <.001 .490 - - - 0.995
83 0.038 <.001 .507 1.168 0.109 <.001 .182 0.998
27 0.048 <.001 .331 1.470 0.076 <.001 .464 0.993
51 0.055 <.001 .749 0.602 0.251 .029 .085 0.993
93 0.063 <.001 .447 1.305 0.229 <.001 .242 0.988
21 0.148 <.001 .526 1.489 0.246 <.001 .353 0.979
47 0.053 <.001 .676 1.042 0.182 <.001 .182 0.994
07 0.087 <.001 .449 1.437 0.138 <.001 .485 0.990
ion coefficients (beta) and model R square obtained in linear regression models.
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of excessive use. This implies that among those catego-
rized as ‘non-excessive users’, a fraction have filled pre-
scriptions exceeding the Norwegian national guidelines
limits for prescriptions of opioids, benzodiazepines and
z-hypnotics. For this reason, the prevalence of excessive
use of these drugs may have been underestimated.
Another limitation is that filled prescriptions may not
necessarily have been entirely consumed by the recipi-
ents. Some drugs may have been diverted (sold or given
away to others) or been lost, wasted or returned unused
to the pharmacy and this is probably more likely to have
occurred among excessive users. However, drug users
may have supplemented their drug access with illegal or
diverted drugs. Thus, the prescription register base data
do not provide a perfect and accurate picture of exces-
sive use (whatever the definition is).
Finally, the data set dates 10 years back in time. While
figures for total sales and prevalence of excessive use for
each drug may change over time, for instance in re-
sponse to change in scheduling of particular drugs, the
mechanisms underlying the strong associations between
total sales and excessive use are probably less subject to
change over time. In fact, the 10 drugs we studied dif-
fered hugely with respect to total sales and prevalence of
users and for all these we found strong associations be-
tween sales and excessive use. This suggests that the
strength of these associations is not very sensitive to the
level of sales. Yet, further studies are needed to assess
the generalizability of the findings both over time and
across jurisdictions.
Implications
These findings are important as they show that changes –
or differences – in excessive use of prescription drugs can
be predicted with some accuracy on the basis of sales data
only. Consequently, this may also apply to the prevalence
of problems related to such use. In the absence of a
programme for individual monitoring of prescription drug
use, drug sales at the aggregate level thus seems to provide
a useful proxy tool for assessment of variation in excessive
drug use and may be a useful indicator of prevalence of ex-
cessive use in studies evaluating possible impacts of policy
changes or other interventions targeting excessive psycho-
tropic drug use. For instance, the increase in problems con-
nected with prescription opioids in the USA [31] could
have been predicted by the sharp increase in sales of these
drugs alone [32].
Further research in this area is warranted and may
take several directions. For instance, replications of the
present study on prescription drugs with an abuse po-
tential could address external validity of the present
findings. It would be important to address whether these
distributional patterns apply to other - often widely used- addictive prescription drugs, such as oxycodone and
methylphenidate, and whether they apply also to non-
addictive drugs. Moreover, it will be highly important to
assess the prescribers’ role in excessive drug use. For in-
stance, more knowledge is needed regarding the extent
of ‘doctor shopping’ among excessive drug users, as well
as a better understanding of the process and interaction
between patient and prescriber that underlie the devel-
opment of excessive use of prescribed drugs.
Conclusions
Despite that access to psychotropic drugs is subject to a
strong individual control through clinicians’ prescribing,
a non-negligible proportion of psychotropic drug users
have filled prescriptions within a year clearly indicating
excessive use, and these excessive users account for a
disproportionately large fraction of the sales of these drugs.
The sales vary significantly between regions and this vari-
ation is closely associated with the prevalence of excessive
users. This suggests that sales figures as such may be used
as an indicator to monitor variations in excessive use be-
tween regions and over time, and to evaluate interventions
targeting over-prescription and excessive use.
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